If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Lyumjev ® (insulin lispro - aabc) injection
100 units/mL, 200 units/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What are the commercial presentations of Lyumjev® (insulin lispro-aabc)?
The commercial presentations of Lyumjev 100 units/mL are similar to those of Humalog at the same concentration, and the Lyumjev 200 units/mL KwikPen® mirrors the Humalog 200 units/mL KwikPen.
Commercial Presentations
The commercial presentations of Lyumjev® (insulin lispro-aabc) 100 units/mL are similar to those of Humalog® (insulin lispro injection) 100 units/mL, and the Lyumjev 200 units/mL KwikPen® (Pen) mirrors the Humalog 200 units/mL Pen (Commercial Presentations of Lyumjev - Dosage Forms and Strengths).1
|
Lyumjev 100 units/mL |
Lyumjev 200 units/mL |
10-mL vial |
Yes |
No |
3-mL KwikPen® |
Yes |
Yes |
3-mL Junior KwikPen® |
Yesa |
No |
3-mL Tempo Pen™ |
Yes |
No |
3-mL cartridge |
Yesa |
No |
Abbreviation: Lyumjev = Lyumjev® (insulin lispro-aabc).
aNot commercially available in the US market.
Enclosed Prescribing Information
References
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2Lyumjev [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
Date of Last Review: March 15, 2022